Comparative Study Between Two Adjuvant Drugs to Bupivacaine for Post-operative Epidural Analgesia in Abdominal Surgeries

Sponsor
Ain Shams University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05323214
Collaborator
(none)
75
1
3
14
5.4

Study Details

Study Description

Brief Summary

Epidural analgesia is associated with early postoperative mobilization and rehabilitation with minimally associated pain and discomfort. Analgesic effect of local anesthetics is augmented by addition of adjuvants in epidural anesthesia ensuring satisfactory postoperative period. This study evaluates the effect of dexmedetomidine and fentanyl as additives to bupivacaine for epidural analgesia.

Condition or Disease Intervention/Treatment Phase
  • Drug: Control Analgesic regimen
  • Drug: Fentanyl Analgesic regimen
  • Drug: Dexmedetomidine Analgesic regimen
Phase 4

Detailed Description

The aim of the study is to evaluate the effect of dexmedetomidin and fentanyl as adjuvants to bupivacaine for postoperative epidural analgesia in abdominal surgeries regarding block characteristics, post-operative analgesia, hemodynamic changes and any anticipated side effects.

  • Type of Study: Prospective randomized comparative clinical study.

  • Study Setting: The operating theatres of Ain Shams University Hospitals

  • Study Period: One year

  • Sampling Method: Random sampling Patients randomly allocated by computer generated randomization and using opaque sealed envelopes to one of the three study groups according to the adjuvant drug used in postoperative analgesia.

  • Sample Size: Total 75 cases divided into 25 cases in each group. Kiran et al. (2018) reported a rather large effect size comparing onset to sensory block and time to maximum motor block. In a one-way ANOVA study, sample sizes of 25 cases per group in three groups whose means are to be compared. The total sample of 75 subjects achieves 80% power to detect differences among the means versus the alternative of equal means using an F test with a 0.0500 significance level. The size of the variation in the means is represented by the effect size = 0.4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Supportive Care
Official Title:
Comparative Study Between Dexmedetomidine and Fentanyl as Adjuvants to Bupivacaine for Post-operative Epidural Analgesia in Abdominal Surgeries
Actual Study Start Date :
Aug 1, 2021
Anticipated Primary Completion Date :
Aug 31, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Control group

Normal saline 2 ml will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.

Drug: Control Analgesic regimen
testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia
Other Names:
  • Epidural Bupivacaine
  • Other: Fentanyl group

    Fentanyl 2 ml (100 μg) will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.

    Drug: Fentanyl Analgesic regimen
    testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia
    Other Names:
  • Epidural Fentanyl Bupivacaine
  • Other: Dexmedetomidine group

    Dexmedetomidine 1 ml (100 μg) plus 1 ml normal saline will be mixed with 48 ml bupivacaine 0.125% in an elastomeric pump. The rate of epidural infusion will be 5ml/hr for the postoperative 24 hours.

    Drug: Dexmedetomidine Analgesic regimen
    testing the efficiency of Dexmedetomidine as an adjuvant drug to bupivacaine in epidural analgesia
    Other Names:
  • Epidural Dexmedetomidine Bupivacaine
  • Outcome Measures

    Primary Outcome Measures

    1. Onset of sensory analgesia [24 hours]

      will be assessed by pin prick and cold application from the start of epidural infusion till scoring 1 at the 3 point scale. Assessment will be done every 5 minutes until the onset of sensory block using a 3-point scale: 0=normal sensation, 1=loss of sensation of pin prick (analgesia), and 2=loss of sensation of touch (anesthesia).

    2. Duration of analgesia [24 hours]

      time from starting epidural infusion to the time of the first request for additional pain medication

    Secondary Outcome Measures

    1. Postoperative pain score [24 hours]

      for 24 hours using the Visual Analogue Scale ranging from 0 to 10 (0 - no pain, 10 - worst pain ever) at 0, 2, 6, 12 and 24 hrs after starting epidural infusion.

    2. Analgesic consumption [24 hours]

      during the 24 hours following epidural infusion.

    3. The motor block [24 hours]

      will be assessed if occurred by Bromage three point score (0-3) for the lower extremity during the 24 hours following epidural infusion where 0: no motor impairment (able to move the hip, knee, and ankle joints); unable to raise either extended leg (able to move joints of knee and ankle); unable to raise extended leg and flex knee (able to move joint of ankle); 3; unable to move knee and foot.

    4. Post operative Mean arterial Blood pressure [24 hours]

      Mean arterial pressure in mmHg will be monitored continuously and recorded just before the initiation of epidural infusion and thereafter at 2, 6, 12 and 24 hrs. postoperatively during the 24 hours following epidural infusion

    5. Post operative Heart rate [24 hours]

      Heart rate (HR) in beats per minute (bpm) will be monitored continuously and recorded just before the initiation of epidural infusion and thereafter at 2, 6, 12 and 24 hrs. postoperatively during the 24 hours following epidural infusion

    6. Post operative Peripheral oxygen saturation [24 hours]

      Peripheral oxygen saturation in blood (SpO2) will be monitored continuously and recorded just before the initiation of epidural infusion and thereafter at 2, 6, 12 and 24 hrs. postoperatively during the 24 hours following epidural infusion

    7. Anticipated adverse events [24 hours]

      like postoperative nausea and vomiting during the 24 hours from the start of epidural analgesia

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • ASA I or ASA II patients.

    • Age group: 21-70 years old.

    • BMI ≤40

    • Duration of procedure ≤ 180 minutes.

    Exclusion Criteria:
    • Patients with known neurologic and psychiatric illness will be excluded from the study.

    • Contraindications for epidural anesthesia as patient refusal, bleeding or coagulation test abnormalities, local skin infection at spinal lumbar region, raised intracranial pressure and hypovolemia

    • Spine abnormalities.

    • Systemic disorders like hematological, respiratory, cardiac, renal or hepatic insufficiency.

    • Allergy to any of the drugs used in the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ain Shams University Hospitals Cairo Egypt

    Sponsors and Collaborators

    • Ain Shams University

    Investigators

    • Study Chair: Bahaa Eldin E Hassan, Professor, Department of Anesthesia, Intensive care and pain management, Ain Shams University.
    • Study Director: Hadeel M Abd Elhamid, Professor, Department of Anesthesia, Intensive care and pain management, Ain Shams University.
    • Study Director: Mohamed A Saleh, MD, Department of Anesthesia, Intensive care and pain management, Ain Shams University.
    • Study Director: Ibrahim A Ibrahim, MD, Department of Anesthesia, Intensive care and pain management, Ain Shams University.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Ain Shams University
    ClinicalTrials.gov Identifier:
    NCT05323214
    Other Study ID Numbers:
    • FMASU MD 121/2021
    First Posted:
    Apr 12, 2022
    Last Update Posted:
    Jul 15, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 15, 2022